학술논문

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
Document Type
Article
Source
In: The Lancet Infectious Diseases. (The Lancet Infectious Diseases, April 2021, 21(4):493-506)
Subject
Language
English
ISSN
14744457
14733099